Physician profile
Donna Marchant
NPI 1275603318
$1,665.45
in general payments reported to CMS, 2019-2025
12 companies · $405 in 2025
The $405 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $40.64 · 2021: $64.26 · 2022: $195 · 2023: $296 · 2024: $665 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,270 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,270.35 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $596.78 | 2023-2025 | |
| Amgen INC. | $216.41 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $146.73 | 2021-2025 | |
| Edwards Lifesciences Corporation | $140.51 | 2020-2025 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $135.47 | 2022-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $124.80 | 2022-2024 | Micra, Selectsecure, Cobalt Dr Mri Surescan |
| Irhythm Technologies, INC. | $119.68 | 2020-2024 | Zio Monitor, Zio Xt Patch |
| Actelion Pharmaceuticals US, INC. | $94.99 | 2024 | Uptravi, Opsumit |
| Alnylam Pharmaceuticals INC. | $25.75 | 2025 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $22.25 | 2024 | Arcalyst |
| Abiomed | $21.20 | 2023 | Impella |
| Insmed, INC. | $20.88 | 2023 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Marchant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.